BioLineRx Ltd. (BLRX)
BLRX Stock Price Chart
Explore BioLineRx Ltd. interactive price chart. Choose custom timeframes to analyze BLRX price movements and trends.
BLRX Company Profile
Discover essential business fundamentals and corporate details for BioLineRx Ltd. (BLRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jul 2011
Employees
28.00
Website
https://www.biolinerx.comCEO
Philip A. Serlin CPA, CPA, MBA
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BLRX Financial Timeline
Browse a chronological timeline of BioLineRx Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 Mar 2026
Upcoming earnings on 24 Nov 2025
EPS estimate is -$0.41.
Earnings released on 14 Aug 2025
EPS came in at -$1.00 falling short of the estimated -$0.35 by -185.71%, while revenue for the quarter reached $304.00K , missing expectations by -60.86%.
Earnings released on 27 May 2025
EPS came in at $1.39 surpassing the estimated -$0.84 by +265.48%, while revenue for the quarter reached $255.00K , missing expectations by -86.04%.
Earnings released on 25 Mar 2025
EPS came in at $6.00 surpassing the estimated -$4.20 by +242.86%, while revenue for the quarter reached $11.75M , beating expectations by +52.22%.
Stock split effective on 30 Jan 2025
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 25 Nov 2024
EPS came in at -$2.80 falling short of the estimated -$0.05 by -5.50K%, while revenue for the quarter reached $4.94M , missing expectations by -5.51%.
Earnings released on 15 Aug 2024
EPS came in at $0.40 surpassing the estimated -$0.14 by +385.71%, while revenue for the quarter reached $5.39M , beating expectations by +37.23%.
Earnings released on 28 May 2024
EPS came in at -$0.01 surpassing the estimated -$0.29 by +96.55%, while revenue for the quarter reached $6.86M , beating expectations by +0.81%.
Earnings released on 26 Mar 2024
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%, while revenue for the quarter reached $4.80M , beating expectations by +60.00%.
Earnings released on 20 Nov 2023
EPS came in at -$12.00 falling short of the estimated -$7.20 by -66.67%.
Earnings released on 30 Aug 2023
EPS came in at -$12.00 falling short of the estimated -$6.40 by -87.50%.
Earnings released on 24 May 2023
EPS came in at -$6.00 falling short of the estimated -$5.60 by -7.14%.
Earnings released on 22 Mar 2023
EPS came in at -$3.60 surpassing the estimated -$5.60 by +35.71%.
Earnings released on 15 Nov 2022
EPS came in at -$6.00 surpassing the estimated -$6.40 by +6.25%.
Earnings released on 16 Aug 2022
EPS came in at -$6.40 falling short of the estimated -$5.60 by -14.29%.
Earnings released on 11 May 2022
EPS came in at -$4.00 surpassing the estimated -$6.00 by +33.33%.
Earnings released on 16 Mar 2022
EPS came in at -$3.20 surpassing the estimated -$5.60 by +42.86%.
Earnings released on 18 Nov 2021
EPS came in at -$9.20 falling short of the estimated -$5.20 by -76.92%.
Earnings released on 18 Aug 2021
EPS came in at -$6.00 falling short of the estimated -$4.80 by -25.00%.
Earnings released on 26 May 2021
EPS came in at -$10.80 falling short of the estimated -$6.00 by -80.00%.
Earnings released on 23 Feb 2021
EPS came in at -$24.40 falling short of the estimated -$10.00 by -144.00%.
Earnings released on 23 Nov 2020
EPS came in at -$12.00 surpassing the estimated -$14.40 by +16.67%.
BLRX Stock Performance
Access detailed BLRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.